Novo Alle 1
45 44 44 88 88
Full-time employees: 57,089
|Mr. Lars Fruergaard Jorgensen||Pres, CEO & Member of Management Board||4.64M||N/A||1966|
|Mr. Karsten Munk Knudsen||Exec. VP, CFO & Member of the Management Board||1.84M||N/A||1971|
|Mr. Henrik Ehlers Wulff||Exec. VP of Product Supply, Quality & IT and Member of the Management Board||1.85M||N/A||1970|
|Ms. Camilla Sylvest||Exec. VP of Commercial Strategy & Corp. Affairs and Member of the Management Board||1.81M||N/A||1972|
|Dr. Martin Holst Lange||Exec. VP of Devel. & Member of the Management Board||1.75M||N/A||1970|
|Dr. Marcus Schindler Ph.D.||EVP of Research & Early Devel., Chief Scientific Officer & Member of the Management Board||1.75M||N/A||1966|
|Mr. Maziar Mike Doustdar||Exec. VP of International Operations & Member of the Management Board||N/A||N/A||1970|
|Mr. Douglas J. Langa||Exec. VP of North America Operations & Member of Management Board||N/A||N/A||1966|
|Mr. Ludovic Helfgott||Exec. VP, Head of Rare Disease & Member of Management Board||N/A||N/A||1974|
|Ms. Tania Sabroe||Exec. VP of Global People & Organisation and Member of Management Board||N/A||N/A||N/A|
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S’s ISS governance QualityScore as of 1 June 2023 is 2. The pillar scores are Audit: 2; Board: 3; Shareholder rights: 10; Compensation: 1.